golongan beta laktam

. Astiti PMA, Mukaddas A, Rabbana SA. Identifikasi Drug Related Problems (DRPs) Pada Pasien Pediatri Radang paru-paru Komunitas di Instalasi Rawat Mengadar RSD Madani Kawasan Sulawesi Tengah: Identification of Drug Related Problems In Pediatric Patients With Community Acquired Pneumonia at Madani Hospi. J Farm Galen (Galenika J Pharmacy). 2017;3(1):57–63. https://doi.org/10.22487/j24428744.2017.v3.i1.8140

. Efni Y, Machmud R, Pertiwi D. Faktor Risiko nan Berhubungan dengan Kejadian Pneumonia pada Balita di Kelurahan Air Tawar Barat Padang. J Kesehat Andalas. 2016;5(2):365–70. https://doi.org/10.25077/jka.v5i2.523

. Han X, Zhou F, Li H, Xing X, Chen L, Wang Y, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired radang paru-paru. BMC Infect Dis. 2018;18(1):1–11. https://doi.org/10.1186/s12879-018-3098-5

. Rivero-Calle I, Cebey-López M, Pardo-Seco J, Yuste J, Redondo E, Vargas DA, et al. Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMO-ES-RISK project). BMJ Open Respir Res. 2019;6(1):1–9. https://doi.org/10.1136/bmjresp-2018-000359

. Aston SJ. Pneumonia in the developing world: Characteristic features and approach to management. Respirology. 2017;22(7):1276–87. https://doi.org/10.1111/resp.13112

. Petrosillo N, Cataldo MA, Pea F. Treatment options for community-acquired pneumonia in the elderly people. Expert Rev Inkompatibel Infect Ther. 2015;13(4):473–85. https://doi.org/10.1586/14787210.2015.1021783

. Viasus D, Núñez-Ramos JA, Viloria SA, Carratalà J. Pharmacotherapy for community-acquired radang paru-paru in the elderly. Expert Opin Pharmacother. 2017;18(10):957–64. https://doi.org/10.1080/14656566.2017.1340940

. Kementerian Kesehatan RI. Kanun Menteri Kesehatan Republik Indonesia. Peratur Nayaka Kesehat No 2406 TAHUN 2011 adapun Pedoman Umum Pengguna Antibiot. 2011;73.

. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):E45–67. https://doi.org/10.1164/rccm.201908-1581ST

. Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT, et al. Pharmacotherapy principles & practice. 2016.

. Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2014;70(4):1219–25. https://doi.org/10.1093/jac/dku479

. Karino F, Deguchi N, Kanda H, Ohe M, Kondo K, Tada M, et al. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics. J Infect Chemother. 2013;19(1):98–102. https://doi.org/10.1007/s10156-012-0463-y

. Namkoong H, Kameyama Y, Yasuda H, Nakayama S, Kaneko H, Kawashima C, et al. The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly. J Infect Chemother. 2014;20(6):356–60. https://doi.org/10.1016/j.jiac.2013.12.010

. Chapman TM, Perry CM. Cefepime: A review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2(1):75–107. https://doi.org/10.1007/BF03256641

. Lodise TP, Kwa A, Cosier L, Gupta R, Smith RP. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007;51(11):3977–82. https://doi.org/10.1128/AAC.00006-07

. Murcia JM, González-Comeche J, Marín A, Barberán J, Granizo JJ, Aguilar L, et al. Clinical response to ertapenem in severe community-acquired pneumonia: A retrospective series in an elderly population. Clin Microbiol Infect. 2009;15(11):1046–50. https://doi.org/10.1111/j.1469-0691.2009.02843.x

. Yanagihara K, Fukuda Y, Seki M, Izumikawa K, Higashiyama Y, Miyazaki Y, et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired radang paru-paru. Intern Med. 2006;45(17):995–9. https://doi.org/10.2169/internalmedicine.45.1717

. Raschilas F, Tigoulet F, Durant R, Blain H, Jeandel C. Ertapanem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc. 2004;52(10):1526–32. https://doi.org/10.1111/j.1532-5415.2004.52479_11_1.x

. Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, et al. Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. Eur J Intern Med. 2015;26(5):330–7. https://doi.org/10.1016/j.ejim.2015.04.002

. Okimoto Tepi langit, Kurihara T, Honda N, Asaoka N, Fujita K, Ohba H, et al. Clinical effect of ampicillin with β-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly. J Infect Chemother. 2003;9(2):183–6. https://doi.org/10.1007/s10156-003-0233-Y

. Grossman RF, Campbell DA, Landis SJ, Garber GE, Murray G, Stiver HG, et al. Treatment of community-acquired pneumonia in the elderly: The role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother. 1999;43(4):549–54. https://doi.org/10.1093/jac/43.4.549